Navigation Links
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
Date:1/9/2009

BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-191 (R7227) in combination with Pegasys(R) (interferon alfa-2a) and Copegus(R) (ribavirin) in patients chronically infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 80676348. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80676348.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
4. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
10. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
11. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Mass., Dec. 16 Boston Scientific Corporation (NYSE: ... Board of Directors has elected Nelda Connors as a ... of the Electrical and Metal Products division of Tyco ... Eaton Corporation, holding several positions in operations and general ... in a number of executive and management capacities with ...
(Date:12/16/2009)... Siemens Healthcare today announced a series ... to help healthcare providers pursue meaningful ... the HITECH provision of the American Recovery ... zero-percent interest terms for qualified customers, the ... associated with their technology investment while meeting ...
(Date:12/16/2009)... 16 BioSpecifics Technologies Corp. (Nasdaq: ... class collagenase-based products, today announced top-line efficacy and ... of XIAFLEX(TM) for the treatment of Peyronie,s disease. ... inelastic collagen on the shaft of the penis, ... intercourse difficult or impossible in advanced cases. The ...
Breaking Medicine Technology:Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 1CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 2CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 3CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 4Wet ethanol production process yields more ethanol and more co products 10667 1Wet ethanol production process yields more ethanol and more co products 10667 2Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 60993 1Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 60993 2
... DuoCort AB,today announced that results of the Phase ... dual release hydrocortisone tablets for adrenal insufficiency,will be ... on,April 30 in Budapest. The trial evaluated the ... healthy,volunteers., The Phase I study showed that both ...
... BioDelivery,Sciences International, Inc. (Nasdaq: BDSI) announced today,statistically ... with breakthrough pain in its pivotal Phase ... results are based on,achievement of the primary ... Intensity Difference (SPID), compared to placebo., The ...
Other Medicine Technology:DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6
(Date:12/16/2009)... -- Smart Balance, Inc. (Nasdaq: SMBL ) announced ... two-year stock repurchase program of up to $25 million, ... the confidence we have in the prospects of our ... for all of our shareholders, while at the same ... Smart Balance, Inc. Chairman and Chief Executive Officer. ,, ...
(Date:12/16/2009)... minorities might not gain full benefit from breakthroughs, experts ... embryonic stem cell lines currently used for research come ... , That could mean that non-whites will benefit less ... down the line, experts say. , Blacks could be ... used stem cell lines studied showed any traces of ...
(Date:12/16/2009)... Dec. 16 For wounded U.S. ... Center in Washington, D.C., the holidays can be a ... to travel home rely more than ever on the ... This week, calling home just got easier for Walter ... calling cards, which will provide hundreds of minutes of ...
(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...
(Date:12/16/2009)... an advance that could help ease health and environmental ... development of technology for changing the behavior of nanoparticles ... into the environment. Their study was published in ACS, ... Jarvie from the UK Centre for Ecology and Hydrology ... the production of nanoparticles particles less than 1/1000th ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Behavior modification could ease concerns about nanoparticles 2
... everyday and more than a third hardly ever eat ... ,Researchers with Deakin’s Centre for Physical Activity and ... aged 12—15 years to evaluate their food intake patterns. ... of adolescents fell short of the recommendations outlined in ...
... global biotechnology company, has released// promising early results of a ... could significantly reduce the treatment time, it has been shown. ... trial on telaprevir were announced at Barcelona on Saturday at ... Study of the Liver (EASL). ,This drug ...
... questionnaire prepared by researchers has found that nine out of ... add more to that it was found that at least ... type of bullying in the past year. ... such as threatening physical harm, and indirect, such as excluding ...
... University of Toronto is revealing biochemical processes responsible// for ... pave the way for pharmaceutical applications. ... that play an important role in human health and ... system), scans cells to detect proteins that interact with ...
... scientists at Bonn University have created a software system that ... //With the aid of the software, the visual prosthesis "learns" ... be interpreted by the brain. ,Nearly two dozens of ... implanted with a visual prosthesis. For this purpose, clinicians open ...
... “night owl” complains more symptoms related to insomnia, ... their nocturnal sleeplessness, according to a study. ... and colleagues at Stanford University, consisted of 312 ... evening chronotypes based upon scores on the Morningness-Eveningness ...
Other Medicine News:Health News:Poor Diet Puts Teenagers' Health at Risk 2Health News:New Hepatitis C Drug Shows Promise 2Health News:Harassment in School Affects Majority of Elementary Students 2Health News:Harassment in School Affects Majority of Elementary Students 3Health News:New Technology Reveals Proteins Responsible for Diseases 2Health News:Software System to Improve the Function of Retinal Implants 2Health News:Software System to Improve the Function of Retinal Implants 3Health News:Insomnia-related Symptoms High Among ‘Night Owls 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: